Martin Mayer

Sep 20, 2024 | mdpi.com | Martin Mayer |Thomas Ernst Dorner |Selam Woldemariam |Christoph Gisinger

All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.

Apr 3, 2024 | jclinepi.com | Martin Mayer |East Carolina |Gordon Guyatt |Richard Riley

This paper is only available as a PDF. To read, Please Download here. AbstractPrognostic models incorporate multiple prognostic factors to estimate the likelihood of future events for individual patients based on their prognostic factor values. Evaluating these models crucially involves conducting studies to assess their predictive performance, like discrimination. Systematic reviews and meta-analyses of these evaluation studies play an essential role in selecting models for clinical practice.

Feb 29, 2024 | ebsco.com | Martin Mayer

Welcome to the finale of our four-part series. If you’re just joining, you have two choices: Read this article for the ultra-abridged version or start from the beginning to – in my opinion – get the most out of this series.

Feb 22, 2024 | ebsco.com | Martin Mayer

In contrast to the Cholesterol Treatment Trialists (CTT) individual patient data meta-analyses (IPDMAs), the USPSTF systematic review and meta-analysis (SRMA) uses aggregate data meta-analysis (ADMA). ADMA is more common, in part because of the extensive work required to do IPDMA.

Feb 15, 2024 | ebsco.com | Martin Mayer

CTT IPDMAsIndividual Patient Data Meta-Analysis (IPDMA) is a powerful analytic modality that sometimes offers insights that are not possible with aggregate data or trial-level meta-analyses. So, are these analyses the crème de la crème for the question of statins for primary prevention of cardiovascular disease (CVD)? Well, maybe not. First, the CTT data show the average reduction in LDL-C from taking a statin is about 1 mmol/L.